an initial pilot study of the device demonstrated efficacy with results presented at arvo in may 2011 (view detailed results here).
Plans are underway for expanded studies at 20 medical centers around the world to further evaluate the effectiveness and the safety of the EYEOP1 device to treat glaucoma.